<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815528</url>
  </required_header>
  <id_info>
    <org_study_id>Cat-Ovar_2011</org_study_id>
    <nct_id>NCT01815528</nct_id>
  </id_info>
  <brief_title>Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>Single -Arm, Multicenter Phase-II Trial for Catumaxomab and Chemotherapy in Patients With Recurrent Ovarian Cancer to Investigate the Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy Regimes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JSehouli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single -arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with
      recurrent ovarian cancer to investigate the feasibility and clinical activity of initial
      intraperitoneal catumaxomab followed by chemotherapy regimes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of close sequential combination of catumaxomab and established chemotherapy regimens</measure>
    <time_frame>Approximately 5 months after start of treatment per patient</time_frame>
    <description>Feasibility of close sequential combination of catumaxomab and established chemotherapy regimens defined by rate of patients with at least 4 chemotherapy cycles following 4 applications of catumaxomab within 20 days as described in the scope of this clinical trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events as a measure of safety and tolerability</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Overall safety evaluation, including cytokine related toxicities (safety score catumaxomab
number and severity of adverse events
number of patients with AEs
occurrence of cytokine release related symptoms
hospitalization frequency and duration
changes in clinically relevant laboratory values (hematology, clinical chemistry, coagulation, and urinalysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who can receive all 4 applications of catumaxomab within 20 days and who are able and committed to receive further mono chemotherapy</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Percentage of patients who can receive all 4 applications of catumaxomab within 20 days and who are able and committed to receive further mono chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who can start chemotherapy after a maximum of 4-7 days after last catumaxomab application</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Percentage of patients who can start chemotherapy after a maximum of 4-7 days after last catumaxomab application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with no signs of malignant ascites at time of progression or change of therapeutic strategy</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Percentage of patients with no signs of malignant ascites at time of progression or change of therapeutic strategy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puncture-free interval (defined as paracentesis-free interval after last catumaxomab application/ removal of catheter)</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Puncture-free interval (defined as paracentesis-free interval after last catumaxomab application/ removal of catheter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) according to RECIST and/or CA-125 response rate</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Time to progression (TTP) according to RECIST and/or CA-125 response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) defined as patients with complete or partial response and duration of response (according to RECIST and/or CA-125 response)</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Overall response rate (ORR) and duration of response (according to RECIST and/or CA-125 response) of second or third or fourth line chemotherapy and compare with historical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment free interval to subsequent therapy (defined as duration of the interval between last chemotherapy application and start of next chemotherapy</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>To assess treatment free interval to subsequent therapy (defined as duration of the interval between last chemotherapy application and start of next chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PFS according to RECIST and/or CA-125 response rate, OS</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>To assess PFS according to RECIST and/or CA-125 response rate, OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess quality of life over time as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>To assess quality of life over time as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential predictive clinical factors for response to catumaxomab</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Analysis of potential predictive clinical factors for response to catumaxomab (e.g. amount of ascites, histology, relative lymphocyte count)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Recurrent Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Catumaxomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catumaxomab treatment followed by an established chemotherapy regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab</intervention_name>
    <description>Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:
10 µg on day 0
20 µg on day 3
50 µg on day 7
150 µg on day 10</description>
    <arm_group_label>Catumaxomab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed epithelial ovarian cancer, primary
             peritoneal carcinomatosis or fallopian tube cancer

          -  Recurrent ovarian cancer disease

          -  Signs for progression either measurable disease according to RECIST or CA 125 increase
             according the GCIG-criteria or clinical symptoms of tumor progression according to
             RECIST

          -  Radiologically and cytologically confirmed malignant ascites possible to puncture

          -  Life expectancy ≥ 12 weeks

          -  Age ≥ 18 years

          -  ECOG performance status at least 1

          -  No prior operation or, in case of prior operation, the patient must be recovered
             therefrom. The operation must be performed at least 4 weeks prior to start of study
             drug

          -  Capable of understanding the purposes and risks of the study, willing and able to
             participate in the study, and written informed consent

          -  Non-childbearing potential or negative pregnancy test

        Exclusion Criteria:

          -  known brain metastases

          -  Concomitant cancer, chemo- or radiotherapy (except for local radiation therapy for
             bone marrow metastases)

          -  Any investigational product within 2 weeks prior to first administration of
             catumaxomab

          -  In cases of previous exposure to investigational product, cancer-, chemo-, immune- or
             radiotherapy (except for local radiation therapy for bone marrow metastasis):

        not sufficiently recovered from previous treatment (toxicity present) based on adequate
        laboratory values and general status according to other in-/exclusion criteria (i.e. this
        might be less than 1 or 2 weeks after a weekly or bi-weekly scheduled previous therapy
        regimen)

          -  Patients must not have been exposed to nitrosoureas or mitomycin C within 6 weeks
             prior the first infusion of catumaxomab

          -  Abnormal organ or bone marrow function

          -  Use of immune-suppressive agents for the past 4 weeks prior to first administration of
             catumaxomab. For regular use of systemic corticosteroids patients should only be
             included after stepwise discontinuation to be free of steroids for a minimum of 5 days
             prior to study entry

          -  Any known active and chronic infection

          -  Known HIV infection and / or hepatitis B virus or hepatitis C virus

          -  Any other concurrent disease or medical conditions that are deemed to interfere with
             the conduct of the study as judged by the investigator

          -  Known or suspected hypersensitivity to catumaxomab and its analogues in general or to
             murine proteins (from rat or mouse)

          -  Known or suspected hypersensitivity to PLD, topotecan, paclitaxel, gemcitabine or
             their excipients.

          -  Patients with congestive heart failure New York Heart Association (NYHA) Class III and
             IV. Cardiac arrhythmias (except atrioventricular block type I and II, atrial
             fibrillation/flutter bundle brunch block)or other signs and symptoms of relevant
             cardiovascular disease

          -  Body mass index (BMI) &lt; 17 (assessment after ascites drainage)

          -  Inadequate respiratory function in the opinion of the investigator

          -  Presence of complete bowel obstruction

          -  Patients with substance abuse, medical or psychological or social conditions which the
             investigator believes would preclude compliance with the study requirements.

          -  Unwilling or unable to follow protocol requirements

          -  Participation in another clinical study with experimental therapy within 14 days
             before start of treatment

          -  Legal incapacity or limited legal capacity

          -  Subjects housed in an institution on official or legal orders

          -  Pregnancy or lactation period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <last_update_submitted>February 17, 2015</last_update_submitted>
  <last_update_submitted_qc>February 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>JSehouli</investigator_full_name>
    <investigator_title>Prof. Dr. med. Jalid Sehouli</investigator_title>
  </responsible_party>
  <keyword>recurrent epithelial ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

